Key Points
- CEO Marshall Fordyce sold 22,951 shares on April 14 at an average price of $44.05 under a pre-arranged Rule 10b5-1 plan, generating about $1.01 million and reducing his stake by 8.89% to 235,244 shares (≈$10.36M).
- Shares opened at $43.45 with a 12‑month range of $18.76–$56.05 and a market capitalization of $3.10 billion; the company reported a negative EPS of ($1.39) for the most recent quarter and has a negative P/E ratio.
- Analyst sentiment is largely bullish (10 Buys, 1 Hold, 1 Sell) with an average target of $81.45 and several firms raising targets, while institutional and hedge fund ownership is very high at about 99.21%.
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 22,951 shares of the company's stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at $10,362,498.20. The trade was a 8.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marshall Fordyce also recently made the following trade(s):
- On Monday, February 23rd, Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock. The stock was sold at an average price of $41.98, for a total value of $710,511.50.
Vera Therapeutics Price Performance
Shares of NASDAQ:VERA opened at $43.45 on Thursday. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12. Vera Therapeutics, Inc. has a twelve month low of $18.76 and a twelve month high of $56.05. The stock's 50 day moving average is $41.20 and its 200-day moving average is $39.49. The firm has a market capitalization of $3.10 billion, a price-to-earnings ratio of -9.32 and a beta of 1.17.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.05). During the same period in the prior year, the business earned ($0.72) earnings per share. Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. HC Wainwright upped their target price on Vera Therapeutics from $90.00 to $110.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $99.00 to $96.00 and set an "overweight" rating for the company in a research report on Friday, December 19th. Wolfe Research raised Vera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $88.00 price target for the company in a research report on Wednesday, March 11th. The Goldman Sachs Group increased their price target on Vera Therapeutics from $55.00 to $95.00 and gave the company a "buy" rating in a research report on Friday, December 19th. Finally, Bank of America increased their price target on Vera Therapeutics from $48.00 to $66.00 and gave the company a "buy" rating in a research report on Friday, December 19th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $81.45.
View Our Latest Report on Vera Therapeutics
Institutional Investors Weigh In On Vera Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in Vera Therapeutics in the 4th quarter valued at $297,000. Invesco Ltd. raised its position in Vera Therapeutics by 193.3% in the 4th quarter. Invesco Ltd. now owns 89,851 shares of the company's stock valued at $4,550,000 after buying an additional 59,219 shares during the last quarter. KVP Capital Advisors LP bought a new position in Vera Therapeutics in the 4th quarter valued at $1,656,000. XTX Topco Ltd bought a new position in Vera Therapeutics in the 4th quarter valued at $508,000. Finally, Virtus Investment Advisers LLC grew its stake in Vera Therapeutics by 5.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company's stock valued at $271,000 after purchasing an additional 290 shares during the period. 99.21% of the stock is owned by hedge funds and other institutional investors.
About Vera Therapeutics
(
Get Free Report)
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
